Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Wysocki who wrote (1314)	10/3/1999 2:14:00 PM
From: Sean Janzen	Respond to of 1501

The rating came out September 20, three days before the AGM. I understand IZP management has ambitious plans for the next 12-18 months. It will be interesting to see if the company can accomplish its goals.

To: Bruce Wysocki who wrote (1314)	10/19/1999 12:10:00 AM
From: Sean Janzen	Read Replies (1) \| Respond to of 1501

It is ironic that McBeath's theme for 2000 is building value considering the Royal Bank's 12 month prediction of $2.25. Very reminiscent of the BS we endured under Dr. S. On the positive the company has a lot of cash to burn. Let's hope they achieve their goals. By the end of Q4 2000 IZP expects to have 5 drugs in Human Clinical Trials, two of which should be in Phase II. I'm not holding my breath for great things in 2000. The great gains should occur when IZP gets a drug into Phase III. IZP please prove me wrong.